Financial Performance - The total operating revenue for the fiscal year 2024 reached RMB 8,466,309,803.08, representing a 4.51% increase compared to RMB 8,100,844,707.33 in 2023[10] - The net profit attributable to shareholders of the listed company decreased by 5.33% to RMB 470,023,746.08 from RMB 496,512,201.25 in the previous year[10] - The basic earnings per share for 2024 was RMB 0.69, a decrease of 6.76% from RMB 0.74 in 2023[10] - The company proposes a final dividend of RMB 0.25 per share for the year 2024, based on a total issued share count of 689,776,535 shares[19] - The company reported a total comprehensive income of RMB 542,947,084.11, compared to RMB 507,843,039.72 in the previous year, representing an increase of 6.9%[77] - The net profit for the year was RMB 486,714,573.88, a decrease of 3.1% compared to RMB 506,107,025.01 in 2023[77] - The total income tax expense for 2024 reached RMB 46,938,849.44, compared to RMB 26,578,700.01 in 2023, which is an increase of approximately 76.7%[107] - The company reported a total of RMB 187,662,099.63 in dividends for the year 2024, up from RMB 134,936,567.00 in 2023, indicating a growth of about 39.0%[112] Assets and Liabilities - The total assets as of the end of 2024 increased by 8.85% to RMB 9,019,601,567.53 compared to RMB 8,286,166,330.90 at the end of 2023[10] - The total liabilities increased by 8.31% to RMB 3,802,101,150.19 from RMB 3,510,413,044.14 in the previous year[9] - The company's asset-liability ratio stood at 42.15%[41] - The total debt of the company was RMB 1,663,214,000, with cash and cash equivalents amounting to RMB 1,245,023,000[38] - Current assets totaled RMB 3,726,840,162.91 as of December 31, 2024, compared to RMB 3,314,333,616.01 in the previous year, indicating an increase of about 12.48%[72] - The company reported a total inventory of RMB 1,272,856,947.10 as of December 31, 2024, slightly down from RMB 1,312,983,676.75 in 2023, indicating a decrease of about 3.06%[72] Cash Flow - The net cash flow from operating activities improved by 38.58% to RMB 367,610,448.95 from RMB 265,278,895.87 in 2023[10] - Cash and cash equivalents increased by 35.57% to ¥1,245,022,873.47 from ¥918,334,462.29, primarily due to increased bank deposits to meet investment needs[26] - Operating cash inflow increased by 16.06% to ¥8,190,329,183.85 from ¥7,057,191,280.19, driven by enhanced operational efficiency and faster inventory turnover[33] - The net increase in cash and cash equivalents was ¥355,190,755.19, a significant improvement of 255.05% compared to a decrease of ¥229,080,092.64 in the previous year[33] Shareholder Information - The number of registered shareholders as of December 31, 2024, was 76,496, including 39 H-share and 76,457 A-share shareholders[13] - The company issued an additional 7,368,900 A-shares due to the stock option incentive plan during the reporting period[8] - The total number of shares held by major shareholders includes 204,864,092 RMB ordinary shares and 193,314,147 overseas listed foreign shares[16] - The total number of shares held by directors and senior management as of December 31, 2024, is 2,055,050 shares, an increase from 1,215,250 shares in 2023[20] Market and Product Development - The company plans to continue expanding its market presence and invest in new product development to drive future growth[10] - The company achieved sales revenue from new pharmaceutical products, with 22 new formulation product approvals and 5 new raw material drug approvals during the year[45] - The company plans to launch over 50 new products in the next two years, providing strong support for innovation breakthroughs and goal completion by 2025[50] - The company is focusing on expanding its market presence and enhancing product development strategies to drive future growth[85] Operational Efficiency - The company reported a 25.05% decrease in selling expenses, totaling ¥584,739,997.94 compared to ¥780,171,394.31, reflecting cost control measures[30] - The company experienced a 76.60% increase in income tax expenses, amounting to ¥46,938,849.44, attributed to higher profitability in a higher tax rate environment[30] - The company’s liquidity ratios include a current ratio of 133.31% and a quick ratio of 87.78% as of December 31, 2024[37] Research and Development - Research and development expenses were RMB 413,182,811.71, slightly down from RMB 419,239,700.90 in 2023[76] - The goal is to obtain over 15 drug approvals in the year, enhancing the R&D and transformation capabilities of active pharmaceutical ingredients[54] - The company is advancing the development of innovative drugs like OAB-14 and optimizing production processes to enhance competitiveness[55] Strategic Initiatives - The company completed the acquisition of its wholly-owned subsidiary, Ronghua (Zibo) Property Service Co., Ltd.[38] - The company introduced a green channel mechanism for R&D and production transformation, enhancing development vitality and achieving the introduction of 1 Chinese Academy of Engineering academician and 2 national key talent project members[48] - The company’s strategic cooperation with leading enterprises in the commercial sector has deepened, enhancing its market control[46]
山东新华制药股份(00719) - 2024 - 年度业绩